Literature DB >> 11727839

Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.

G Myklebust1, J T Gran.   

Abstract

OBJECTIVE: To describe the maintenance dose and annual cessation rate of oral corticosteroids in relation to the starting dose in patients with polymyalgia rheumatica (PMR) and temporal arteritis (TA).
METHODS: A prospective two-years observational study of 273 patients with PMR and TA followed by rheumatologists.
RESULTS: Mean daily maintenance dose of prednisolone during the first and second year was 5.7 mg and 4.3 mg for PMR, 6.6 mg and 4.1 mg for TA, and 8.3 mg and 4.7 mg for PMR with TA. There was a strong association between the initial dose and maintenance dose. The rate of steroid cessation after two years in PMR was 24%, in TA 16%, and in PMR with TA 5%.
CONCLUSION: Low initial dose of prednisolone is associated with low maintenance dose. This is important as the majority of patients with PMR and TA will be treated for more than two years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727839     DOI: 10.1080/030097401753180327

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  13 in total

1.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 2.  [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Authors:  F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

Review 3.  Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Authors:  Michael Schirmer; Christian Dejaco; Bhaskar Dasgupta; Eric L Matteson
Journal:  Rheumatol Int       Date:  2015-06-02       Impact factor: 2.631

4.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

5.  Study of professional practices among rheumatologists in Burgundy: initial corticotherapy in polymyalgia rheumatica.

Authors:  Paul Ornetti; Caroline Guillibert-Karras; Jean-François Garrot; Florence Gros; Nathalie Gérard; Laurence Julien; Françoise Pascaud; Thierry Peere; Monique Petit-Perrin; Christine Piroth; Christian Tavernier; Jean-Francis Maillefert
Journal:  Clin Rheumatol       Date:  2010-11-18       Impact factor: 2.980

6.  Long-term glucocorticoid treatment in patients with polymyalgia rheumatica: can we just move a step forward? Comments on "Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis".

Authors:  Ciro Manzo
Journal:  Clin Rheumatol       Date:  2021-08-30       Impact factor: 2.980

Review 7.  Recent advances in temporal arteritis.

Authors:  Carol Redillas; Seymour Solomon
Journal:  Curr Pain Headache Rep       Date:  2003-08

Review 8.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

9.  The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.

Authors:  Marco A Cimmino; Massimiliano Parodi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  BMC Musculoskelet Disord       Date:  2011-05-14       Impact factor: 2.362

Review 10.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.